AquaLOX®

Deliver Joint Health in Formulations Where Taste Matters
Benifit Image
40 mg
The recommended dose for AquaLOX is much lower than many conventional joint health ingredients.
Benifit Image
5 Loxin
AquaLOX is the water-soluble version of one of the world’s best-selling joint health ingredients
Benifit Image
8 Studies
AquaLOX is supported by 8 pre-clinical and clinical studies.

Identity & Quality You Can Trust

AquaLOX is a water-soluble version of PLT’s Boswellia Serrata extract 5-LOXIN®. 5-LOXIN has been clinically demonstrated to improve joint comfort and protect against cartilage degradation. In addition to being water-soluble, AquaLOX represents a major breakthrough with its pleasant taste profile, allowing – for the first time – the opportunity to feature PLT’s leading joint health solutions in taste-sensitive formulations such as chewables, gummies, stick-packs, shots and more.

Good For
Ingredient Solutions
Active Nutrition
Bone, Joint & Muscle
Healthy Aging
Applications
Beverages
Capsules
Chews
Effervescents
Gummies
Powders
RTDs / Shots
Snacks
Soft Gels
Stick Packs

Active/Sports Nutrition

AquaLOX is a perfect addition to pre-workout, post-workout and recovery formulations and can be delivered in a range of product forms.

Fitness woman eating energy bar at gym
Woman practicing yoga, lying in Knees to Chest pose, Apanasana

Bone, Joint & Muscle Health

Joint Health is a huge potential market – but consumers are telling us that they want their joint health solutions to be fast-acting and convenient. AquaLOX can help you deliver new solutions to your customers.

Healthy Aging

Today’s seniors are more active than ever and reach for joint health support to help them maintain their lifestyles. But, even\ younger consumers are aware of the need to support bones and joints to help them get the most out of their years.

Grandparents And Granddaughter Walking On Winter Beach
Research

Research that builds trust with consumers.

AquaLOX precursor, 5-LOXIN is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. It has been the subject of 13 pre-clinical studies and 2 human clinical trials. One of the key features of 5-LOXIN in any formulation is the clinical work that has demonstrated efficacy starting at 7 days – at a significantly lower dose (100 mg) than other joint health ingredients. This fast efficacy and low dose allow 5-LOXIN to compete with non-natural or over-the-counter solutions.

Beyond joint comfort and flexibility improvements, 5-LOXIN also positively impacts biological markers associated with joint health and inflammation, including TNFa, CRP, and IL-6. It was also shown to significantly inhibit matrix metalloproteinase (MMP-3), an enzyme that breaks down cartilage, collagen and connective tissues.

INSIGHTS

Sustainability is a Key Value

The starting point for AprèsFlex – Boswellia serrata – is a plant that produces Indian frankincense. It is also known as Indian oli-banum, Salai guggul, and Sallaki in Sanskrit. The plant is native to much of India and the Punjab region that extends into Pakistan. In the last five years, PLT partner Laila Nutra has planted over 10,000 frankincense trees in India. Laila and PLT are committed to the safety and fair treatment of the people who harvest AprèsFlex. We want to support the long-term health and well-being of the tribal culture and the natural environment upon which it relies.

Ingredient Traceability

Every batch of the AquaLOX harvest is assigned a specific batch number and each batch of finished product is traceable to specific region and set of trees. AquaLOX x is tested and must comply with predefined specifications for different parameters at different stages of product manufacturing – from raw materials to finished product. Quality is monitored by a multi-disciplinary organization with dedicated departments for taxonomy (botanical Identification), raw material analysis, chemical analysis, microbiology and more

Pharmacokinetic Study Shows AquaLOX Matches 5-LOXIN

In a RDBC crossover clinical trial, healthy adults took either 40 mg AquaLOX (31.2 mg AKBA) or 100 mg 5-LOXIN (30 mg AKBA) in a random order on separate occasions. The results for AUC0-∞ (Area under the curve) showed that similar amounts of total AKBA were absorbed with each product. This demonstrated that the new product form was a highly efficient way of delivering the primary active ingredient.

Resources

Deliver Enhanced Joint Comfort Your Customers Can Feel

PLT has a broad range of joint health solutions that can work in almost any type of product you’re making.